Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients

The current treatment options for epidermal growth factor receptor (EGFR) mutation-positive lung cancer in the elderly with tyrosine kinase inhibitor (TKI) resistance are limited. Although chemotherapy combined with vascular endothelial growth factor inhibitors significantly improves progression-fre...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncology letters 2023-08, Vol.26 (2), p.323, Article 323
Hauptverfasser:	Chen, Yi, Jiang, Nanyuan, Liang, Xiao, Chen, Nan, Chen, Yun, Zhang, Chen, Shi, Junfeng, Guo, Renhua
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer therapies Chemotherapy Consent Disease control Genetic testing Kinases Lung cancer Medical prognosis Mutation Oncology Patients Response rates Software Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!